These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26294723)

  • 1. A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.
    Tedeschi A; Rossi D; Motta M; Quaresmini G; Rossi M; Coscia M; Anastasia A; Rossini F; Cortelezzi A; Nador G; Scarfò L; Cairoli R; Frustaci AM; Dalceggio D; Picardi P; De Paoli L; Orlandi E; Rambaldi A; Massaia M; Gaidano G; Montillo M;
    Haematologica; 2015 Dec; 100(12):e501-4. PubMed ID: 26294723
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase I and II study of pentostatin (Nipent) with cyclophosphamide for previously treated patients with chronic lymphocytic leukemia.
    Weiss MA
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):41-3. PubMed ID: 10877051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
    Shanafelt T; Lanasa MC; Call TG; Beaven AW; Leis JF; LaPlant B; Bowen D; Conte M; Jelinek DF; Hanson CA; Kay NE; Zent CS
    Cancer; 2013 Nov; 119(21):3788-96. PubMed ID: 23922059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
    Kay NE; Geyer SM; Call TG; Shanafelt TD; Zent CS; Jelinek DF; Tschumper R; Bone ND; Dewald GW; Lin TS; Heerema NA; Smith L; Grever MR; Byrd JC
    Blood; 2007 Jan; 109(2):405-11. PubMed ID: 17008537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial.
    Strati P; Lanasa M; Call TG; Leis JF; Brander DM; LaPlant BR; Pettinger AM; Ding W; Parikh SA; Hanson CA; Chanan-Khan AA; Bowen DA; Conte M; Kay NE; Shanafelt TD
    Lancet Haematol; 2016 Sep; 3(9):e407-14. PubMed ID: 27570087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).
    Kempin S; Sun Z; Kay NE; Paietta EM; Mazza JJ; Ketterling RP; Frankfurt O; Claxton DF; Saltzman JN; Srkalovic G; Callander NS; Gross G; Tallman MS
    Acta Haematol; 2019; 142(4):224-232. PubMed ID: 31336367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
    Weiss MA; Maslak PG; Jurcic JG; Scheinberg DA; Aliff TB; Lamanna N; Frankel SR; Kossman SE; Horgan D
    J Clin Oncol; 2003 Apr; 21(7):1278-84. PubMed ID: 12663715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia.
    Kay NE; LaPlant BR; Pettinger AM; Call TG; Leis JF; Ding W; Parikh SA; Conte MJ; Bowen DA; Shanafelt TD
    Expert Rev Hematol; 2018 Apr; 11(4):337-349. PubMed ID: 29460654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
    Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentostatin treatment combinations in chronic lymphocytic leukemia.
    Lamanna N; Kay NE
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):386-92. PubMed ID: 19606074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.
    Kay NE; Strati P; LaPlant BR; Leis JF; Nikcevich D; Call TG; Pettinger AM; Lesnick CE; Hanson CA; Shanafelt TD
    Oncotarget; 2016 Nov; 7(48):78269-78280. PubMed ID: 27861157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
    Hillmen P; Robak T; Janssens A; Babu KG; Kloczko J; Grosicki S; Doubek M; Panagiotidis P; Kimby E; Schuh A; Pettitt AR; Boyd T; Montillo M; Gupta IV; Wright O; Dixon I; Carey JL; Chang CN; Lisby S; McKeown A; Offner F;
    Lancet; 2015 May; 385(9980):1873-83. PubMed ID: 25882396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488.
    Oken MM; Lee S; Kay NE; Knospe W; Cassileth PA
    Leuk Lymphoma; 2004 Jan; 45(1):79-84. PubMed ID: 15061201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.
    Kay NE; Wu W; Kabat B; LaPlant B; Lin TS; Byrd JC; Jelinek DF; Grever MR; Zent CS; Call TG; Shanafelt TD
    Cancer; 2010 May; 116(9):2180-7. PubMed ID: 20187101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.
    Shanafelt TD; Lin T; Geyer SM; Zent CS; Leung N; Kabat B; Bowen D; Grever MR; Byrd JC; Kay NE
    Cancer; 2007 Jun; 109(11):2291-8. PubMed ID: 17514743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Dillman RO; Schreeder MT; Hon JK; Connelly EF; DePriest C; Cutter K
    Cancer Biother Radiopharm; 2007 Apr; 22(2):185-93. PubMed ID: 17600465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome.
    Laurenti L; De Padua L; Tarnani M; Piccirillo N; Falcucci P; D'Arena G; Innocenti I; Marietti S; Efremov DG; Chiusolo P; Zini G; Sora' F; Sica S; Leone G
    Ann Hematol; 2011 Jan; 90(1):59-65. PubMed ID: 20625902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
    J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.